KPV CapsulesHealing & Recovery
Oral KPV capsules studied for gut and skin inflammation.
- Status
- Research / not approved
- Developer
- Synthetic alpha-MSH(11-13) tripeptide
- Receptors / target
- C-terminal alpha-MSH(11-13) tripeptide (Lys-Pro-Val); anti-inflammatory via NF-kB/MAPK inhibition; oral uptake via the intestinal PepT1 transporter
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- gut / IBD researchanti-inflammatory signalingintestinal epithelial uptake (PepT1)skin inflammation & wound healing
Overview
KPV Capsules are the oral (capsule) form of KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (Lys-Pro-Val). The molecule is identical to the injectable version; only the route differs. The oral route is mechanistically relevant for KPV because it is taken up by the intestinal PepT1 transporter and has been studied for gut inflammation. All published evidence is preclinical — cell-culture and rodent studies — and KPV is handled as a research-use-only compound with no approved therapeutic indication.
Mechanism
In preclinical work, KPV is taken up into intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter, where it inhibits NF-kB and MAP-kinase signaling and lowers pro-inflammatory cytokines at nanomolar concentrations. This PepT1-mediated gut uptake is what makes an oral format plausible, particularly for local intestinal anti-inflammatory effects. The effect appears largely melanocortin-receptor-independent. These mechanisms are characterized in cells and rodents, not in humans.
Clinical evidence
There are no published human clinical trials of KPV by any route. The efficacy evidence consists entirely of in-vitro and animal studies: oral KPV reduced chemically induced colitis in mice, and hyaluronic-acid nanoparticle delivery improved colonic targeting and outcomes in mouse ulcerative-colitis models. Translation to humans remains unestablished — effective dose, oral bioavailability and clinical benefit in people are all unknown.
Safety profile
Human safety of KPV is essentially unstudied — there are no controlled human trials reporting adverse events, dosing or long-term tolerability. Preclinical rodent studies did not report overt toxicity at the doses used, but animal tolerability does not establish human safety, and human pharmacokinetics are poorly characterized. Research-grade material is of unverified purity. It is not FDA-evaluated and is not WADA-prohibited. Research-use only; nothing here is therapeutic or dosing guidance.
- Days to weeks
No human trials exist. In mouse colitis models oral KPV acted over days to weeks; anecdotal gut use mirrors that window but is unverified in people.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Generally well tolerated in preclinical research; limited human data
- No human clinical trials of oral KPV
- Research-grade material is of unverified purity
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human contraindication data exist for KPV; it has not been studied in controlled human trials, so contraindications cannot be characterized from the literature.
- Human pharmacokinetics are poorly characterized and research-grade material may be of unverified purity; people who are pregnant, breastfeeding, or managing a medical condition have no safety data to rely on.
- Not for human consumption; research use only. Nothing here is therapeutic or dosing guidance.
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs KPV
The injectable/non-capsule form of the same tripeptide
- vs BPC-157 Capsules
Another oral research peptide commonly paired for gut and repair contexts
FAQ
Are KPV capsules FDA-approved?
No. KPV in any form is not approved by the FDA and is sold research-use-only. All published evidence is preclinical (cell-culture and rodent studies).
Why does KPV come as an oral capsule?
The oral route is mechanistically relevant because KPV is taken up by the intestinal PepT1 transporter and has been studied for gut inflammation in mice. However, oral bioavailability and clinical benefit in humans remain unproven.
Is there human evidence that oral KPV works?
No. There are no published human clinical trials of KPV by any route; the colitis findings come from in-vitro and mouse studies.
How does KPV work?
KPV is the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val). In preclinical work it enters intestinal epithelial and immune cells via the PepT1 transporter and inhibits NF-kB and MAP-kinase signaling, lowering pro-inflammatory cytokines at nanomolar concentrations. The effect appears largely melanocortin-receptor-independent, and these mechanisms are characterized in cells and rodents, not humans.
Is KPV banned in sport?
It is not specifically named as a prohibited substance and is not currently WADA-prohibited, but anti-doping lists can change and research-grade material of unverified purity carries independent risk.
How do KPV capsules differ from injectable KPV?
It is the same tripeptide (Lys-Pro-Val) in a different route; only the delivery differs. The oral capsule leans on PepT1 gut uptake for local intestinal anti-inflammatory effects, while the injectable is used systemically. Neither route has human efficacy trials, so both are research-use-only.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.